“We spoke with the CFO, Scott Durbin post announcement this morning. Scott emphasized that while the discounted price of $3.00 relative to yesterday’s closing ($3.83) was disappointing, the newly raised capital is adequate to support continued business expansion into the end of 2019 and removes a financing overhang. The company is still hopeful in receiving clearance from the FDA to run the sexual dysfunction study by the end of Q1, 2018.”,” Mizuho’s analyst wrote.
Several other analysts have also weighed in on VIVE. Cowen set a $11.00 price objective on Viveve Medical and gave the company a buy rating in a research note on Monday, October 23rd. ValuEngine lowered Viveve Medical from a sell rating to a strong sell rating in a research note on Friday, December 1st. Northland Securities initiated coverage on Viveve Medical in a research note on Friday, January 5th. They issued an outperform rating and a $8.00 price objective on the stock. Finally, Ladenburg Thalmann Financial Services reaffirmed a buy rating on shares of Viveve Medical in a research note on Thursday, January 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $10.00.
Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.08). The business had revenue of $4.07 million during the quarter, compared to analyst estimates of $4.10 million. Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The business’s quarterly revenue was up 120.1% compared to the same quarter last year. During the same period last year, the business earned ($0.46) earnings per share. research analysts anticipate that Viveve Medical will post -2.05 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. Neuberger Berman Group LLC acquired a new stake in Viveve Medical in the third quarter valued at about $419,000. TIAA CREF Investment Management LLC acquired a new stake in Viveve Medical in the second quarter valued at about $296,000. ING Groep NV boosted its stake in shares of Viveve Medical by 93.7% during the third quarter. ING Groep NV now owns 325,000 shares of the company’s stock valued at $1,703,000 after purchasing an additional 157,200 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Viveve Medical by 135.4% during the second quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock valued at $3,232,000 after purchasing an additional 258,912 shares in the last quarter. Finally, Numeric Investors LLC acquired a new stake in shares of Viveve Medical during the second quarter valued at about $330,000. 66.89% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Viveve Medical (VIVE) Given “Buy” Rating at Mizuho” was originally posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2018/02/09/viveve-medical-vive-given-buy-rating-at-mizuho.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.